Aimmune Therapeutics has announced that its oral peanut allergy drug, AR101 has met its main goal in a late-stage study. The results have caused Aimmune's shares to go up 18 percent premarket. The drugmaker is aiming for U.S. approval by the end of 2018 and European approval the first half of 2019.
There are currently no approved treatments for peanut allergies, which are the leading cause of death from food-induced allergic reactions in the United States.
Aimmune's data found that 67.2 percent of patients, ages 4 to 7, that were administered AR101 were able to tolerate at least a 600-mg dose of peanut protein in the exit food challenge, compared to 4.0 percent of patients on placebo.
AR101 is sprinkled over food daily and aims to make patients desensitized through small doses of peanut protein.
The positive trial data comes after DBV Technologies SA’s stick-on patch failed to sufficiently desensitize patients with the allergy.
DBV and Aimmune are in a race to become the first treatment for the condition.
Read the Reuters report